AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JUN 26 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in Europe have found a way to enhance the performance of DNA-based human papillomavirus (HPV) vaccines.
"DNA vaccination is a promising approach for inducing both humoral and cellular immune responses," according to Dr. Nico Michel and colleagues at the German Cancer Research Center in Heidelberg and the Netherlands Cancer Institute in Amsterdam. "For immunotherapy of HPV-16-associated diseases the E7 protein is considered a prime candidate, as it is expressed in all HPV-16-positive tumors."
Combining E7 with other proteins can augment its naturally weak immunogenicity, Michel and coauthors reported.
The researchers evaluated the efficacy of a fusion protein consisting of HPV-E7 and VP22, the herpes simplex virus ferry protein. VP22 acts as a protein export signal, they noted.
Combination with VP22 significantly enhanced E7's immunogenicity, study data showed, and enabled the fusion protein to translocate across cells. Further experiments suggested that the benefits conferred by VP22 could also be acheived using any export ...